Immune Checkpoint Inhibitors Market by Type, Indication, Route of Administration, End-Users, Distribution Channel

List of Tables

The Immune Checkpoint Inhibitors Market is projected to reach USD 19.46 billion by 2030 from USD 8.59 billion in 2022, at a CAGR of 10.75% during the forecast period.

Global Immune Checkpoint Inhibitors Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 8.59 billion
Estimated Year Value [2023]	USD 9.47 billion
Forecast Year Value [2030]	USD 19.46 billion
CAGR (%)	10.75%

Immune Checkpoint Inhibitors Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Immune Checkpoint Inhibitors Market.

Based on Type, market is studied across CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor. The PD-L1 Inhibitor is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Hodgkin Lymphoma, Kidney Cancer, Liver Cancer, Lung Cancer, and Solid Cancer. The Kidney Cancer is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.

Based on End-Users, market is studied across Hospitals and Specialty Clinics. The Specialty Clinics is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Immune Checkpoint Inhibitors Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Immune Checkpoint Inhibitors Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Immune Checkpoint Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alphamab Oncolog, ALX Oncology Inc., Astellas Pharma Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., Kintor Pharmaceutical Limited, Merck KGaA, MiNK Therapeutics, Inc., NATCO Pharma Ltd., NextCure, Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Seagen Inc., SQZ Biotechnologies Company, Thermo Fisher Scientific Inc., and Xencor, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Immune Checkpoint Inhibitors Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Immune Checkpoint Inhibitors Market?

3. What is the competitive strategic window for identifying opportunities in the Immune Checkpoint Inhibitors Market?

4. What are the latest technology trends and regulatory frameworks in the Immune Checkpoint Inhibitors Market?

5. What is the market share of the leading vendors in the Immune Checkpoint Inhibitors Market?

6. Which modes and strategic moves are suitable for entering the Immune Checkpoint Inhibitors Market?

Product Code: MRR-FF012EDC38E9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Immune Checkpoint Inhibitors Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cancer across the globe
  - 5.1.1.2. Rising government initiatives for cancer treatment and awareness programs
  - 5.1.1.3. Growing geriatric population and adoption of unhealthy lifestyle
- 5.1.2. Restraints
  - 5.1.2.1. Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research activities for advanced cancer treatments
  - 5.1.3.2. Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
- 5.1.4. Challenges
  - 5.1.4.1. Presence of alternative treatment therapies for cancer
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Immune Checkpoint Inhibitors Market, by Type

6.1. Introduction
6.2. CTLA-4 Inhibitor
6.3. PD-1 Inhibitor
6.4. PD-L1 Inhibitor

7. Immune Checkpoint Inhibitors Market, by Indication

7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Hodgkin Lymphoma
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Solid Cancer

8. Immune Checkpoint Inhibitors Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Immune Checkpoint Inhibitors Market, by End-Users

9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics

10. Immune Checkpoint Inhibitors Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Immune Checkpoint Inhibitors Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Immune Checkpoint Inhibitors Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Alphamab Oncolog
- 15.1.2. ALX Oncology Inc.
- 15.1.3. Astellas Pharma Inc.
- 15.1.4. AstraZeneca PLC
- 15.1.5. Becton, Dickinson and Company
- 15.1.6. Bio-Rad Laboratories, Inc.
- 15.1.7. BioNTech SE
- 15.1.8. Boehringer Ingelheim International GmbH
- 15.1.9. Bristol-Myers Squibb
- 15.1.10. Dr. Reddy's Laboratories Ltd.
- 15.1.11. F. Hoffmann-La Roche AG
- 15.1.12. Genmab A/S
- 15.1.13. GlaxoSmithKline PLC
- 15.1.14. ImmuneSensor Therapeutics Inc.
- 15.1.15. ImmunityBio, Inc.
- 15.1.16. Kintor Pharmaceutical Limited
- 15.1.17. Merck KGaA
- 15.1.18. MiNK Therapeutics, Inc.
- 15.1.19. NATCO Pharma Ltd.
- 15.1.20. NextCure, Inc.
- 15.1.21. Regeneron Pharmaceuticals Inc.
- 15.1.22. Sanofi SA
- 15.1.23. Seagen Inc.
- 15.1.24. SQZ Biotechnologies Company
- 15.1.25. Thermo Fisher Scientific Inc.
- 15.1.26. Xencor, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing